Columns

Pharma Insights
Cancer Care in 2021 and Beyond: Catalytic Trends, Entrants, and Developments to Optimize Care During and Post Pandemic
Elizabeth Oyekan, PharmD, FCSHP, CPHQ February 22, 2021
Pharma Insights
Journeying Through the Past, Present, and Future of Medicare Part D
Andrew Cournoyer, RPh, MBA; Charline Shan, RPh, MPh; Larry Blandford, PharmD—Column Editor, June 17, 2020
Andrew Cournoyer, RPh, MBA, and colleagues explore the beginnings of Medicare Part D and the different dynamics driving…
Engaging Payers
Partnership in Value-Based Care: Becoming and Finding Good Teammates
Lili Brillstein, MPH—Column Editor, May 19, 2020
Lili Brillstein, MPH, reinforces that, to effectively and consistently optimize care, strong integrated delivery teams…
Pharma Insights
Real-World Data Will Continue to Provide Real Value to the Drug Development and Commercialization Process
Sajjad Raza, MD, PhD, MSM; Kathy Lang, PhD, May 19, 2020
Sajjad Raza, MD, PhD, MSM, and Kathy Lang, PhD, provide evidence that the drug development landscape is evolving to a…
Trending From ACCC
Telehealth in the Wake of COVID-19
JCP Editors, May 19, 2020
ACCC reviews their COVID-19 online resources, including a webcast series with episodes that focus on the “how-to” of…
Clinical Pathways GPS
How COVID-19 Will Change the Patient Journey, Reimbursement, and Care Delivery
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor, May 19, 2020
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD, posits that current health care tools and programs such as clinical…
Tools for Transformation
Drivers and Projected Trends for Post-COVID-19 Cancer Care Operations
Gordon Kuntz—Column Editor, May 19, 2020
Gordon Kuntz, Partner, Kuntz Consulting, explores the long-term impacts of the pandemic on cancer care, including…
Editorial
Attend #COA2020 to Prepare for What’s Next in Community Oncology
Nicolas Ferreyros, Director of Communications, Community Oncology Alliance, April 21, 2020
Oncology is changing rapidly as models of care and reimbursement evolve. We have seen this firsthand with the rapid…
Trending From ACCC
Cancer Care in the Time of COVID-19
Randall A Oyer, MD, ACCC President 2020-2021, April 21, 2020
As a community-spread disease, coronavirus 2019 shows us the importance of community—from global, national, state,…
Pharma Insights
Equivalars: Could They Bring Down the Cost of Rx Drugs?
Sejal Jonas, PharmD1; Larry Blandford, PharmD2—Column Editor, April 21, 2020
Sejal Jonas, PharmD, and Larry Blandford, PharmD, describe the way that payers may view equivalars and if drug…
Clinical Pathways GPS
Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs
Matthew Pakizegee, PharmD, MS; Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor; Craig Ornstein, PhD, MA; Uttama Rath, PhD, MS; Jamey Hardesty, MPH, April 21, 2020
Matthew Pakizegee, PharmD, MS, and colleagues discuss the varying roles of patients, providers, payers, policymakers,…
Back to Top